A Study of IBI310 in Treatment of Patients With Advanced Solid Tumors.
Status:
Unknown status
Trial end date:
2021-07-15
Target enrollment:
Participant gender:
Summary
This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability,
pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of single agent of IBI310 and
in combination of sintilimab in patients with advanced solid tumors(Ia) and advanced
melanoma(Ib).